Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity

Current Opinion in Genetics and Development

Volumn 13, Issue 2, 2003, Pages 108-113

  Gill, Grace ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HEAT SHOCK TRANSCRIPTION FACTOR 1; ISOPROTEIN; LYSINE; OXYGENASE; SUMO 1 PROTEIN; SUMO PROTEIN; TRANSCRIPTION FACTOR SP3;

COVALENT BOND; ENZYME SPECIFICITY; EUKARYOTE; GENE EXPRESSION REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; TRANSLATION REGULATION;

EUKARYOTA;

EID: 0037382641     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(03)00021-2     Document Type: Review

References (48)

1. Melchior F. SUMO-nonclassical ubiquitin. Annu. Rev. Cell Dev. Biol. 16:2000;591-626.
2. Muller S., Hoege C., Pyrowolakis G., Jentsch S. SUMO, ubiquitin's mysterious cousin. Nat. Rev. Mol. Cell Biol. 2:2001;202-210.
3. Rodriguez M.S., Desterro J.M., Lain S., Midgley C.A., Lane D.P., Hay R.T. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18:1999;6455-6461.
4. Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., Scheffner M., Del Sal G. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 18:1999;6462-6471.
5. Muller S., Berger M., Lehembre F., Seeler J.S., Haupt Y., Dejean A. c-Jun and p53 activity is modulated by SUMO-1 modification. J. Biol. Chem. 275:2000;13321-13329.
6. Ross S., Best J.L., Zon L.I., Gill G. SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization. Mol. Cell. 10:2002;831-842. • Endogenous Sp3 is shown to be post-translationally modified by SUMO-1 and the major SUMO acceptor site is mapped to a previously defined inhibitory domain. Removal of SUMO-1 from Sp3 by mutation of the acceptor lysines or cotransfection with the SuPr-1 SUMO protease increased transcriptional activation by Sp3. SUMO-1 modification was also shown to regulate the subnuclear localization of Sp3 to the nuclear periphery and nuclear dots. The authors show that covalent attachment of SUMO-1 by gene fusion is sufficient to regulate Sp3 activity and localization.
7. ••] the transcription factor Sp3 is shown to be post-translationally modified by SUMO-1 at a lysine residue in a known inhibitory domain. PIAS1 is shown to interact with Sp3 and stimulate SUMO-modification of Sp3 in vitro. Mutations in Sp3 that prevent SUMO modification in vitro greatly enhance transcriptional activation by Sp3 in vivo. SUMO modification does not alter Sp3 DNA binding activity in vitro.
8. Le Drean Y., Mincheneau N., Le Goff P., Michel D. Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. Endocrinology. 143:2002;3482-3489. • GR is shown to be post-translationally modified by SUMO-1. Overexpression of SUMO-1 was found to stimulate GR-dependent transcription in a promoter-specific manner. In particular, overexpression of SUMO-1 stimulated GR activation from multiple but not single binding sites, suggesting SUMO-1 may regulate synergistic activation by GR.
9. •], mutating the SUMO acceptor lysines was found to increase GR activity at some promoters but not others, suggesting promoter-specific effects of this post-translational modification.
10. Bayer P., Arndt A., Metzger S., Mahajan R., Melchior F., Jaenicke R., Becker J. Structure determination of the small ubiquitin-related modifier SUMO-1. J. Mol. Biol. 280:1998;275-286.
11. Kim K.I., Baek S.H., Chung C.H. Versatile protein tag, SUMO: its enzymology and biological function. J. Cell Physiol. 191:2002;257-268.
12. Rodriguez M.S., Dargemont C., Hay R.T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276:2001;12654-12659.
13. Tatham M.H., Jaffray E., Vaughan O.A., Desterro J.M., Botting C.H., Naismith J.H., Hay R.T. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 276:2001;35368-35374.
14. Kahyo T., Nishida T., Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol. Cell. 8:2001;713-718. • Although the SUMO E1 activating enzyme and E2 conjugating enzyme are sufficient for a low level of sumoylation in vitro, this study shows that PIAS1 acts as a SUMO E3 ligase to stimulate SUMO-modification of the tumor suppressor p53 in vitro and in vivo. Consistent with its role as a SUMO E3 ligase, PIAS1 is shown to interact with both the Ubc 9 E2 conjugating enzyme and the substrate p53. SUMO E3 ligase activity of PIAS1 is dependent on an intact RING domain.
15. Sachdev S., Bruhn L., Sieber H., Pichler A., Melchior F., Grosschedl R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev. 15:2001;3088-3103. • This study identifies PIASy as a SUMO E3 ligase for the Wnt-responsive transcription factor LEF1. PIASy is shown to stimulate SUMO-modification of LEF1 both in vitro and in vivo dependent on the RING domain of PIASy. PIASy represses LEF1-dependent transcription and regulates LEF1 subnuclear localization into nuclear bodies. Regulation of LEF1 activity and localization depends on the RING domain of PIASy but not the major SUMO acceptor sites in LEF1, suggesting that although PIASy E3 ligase activity is required, LEF1 may not be the critical substrate for these functional effects.
16. Pichler A., Gast A., Seeler J.S., Dejean A., Melchior F. The Nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell. 108:2002;109-120. • This paper identifies the nucleoporin component RanBP2 as a SUMO E3 ligase. RanBP2 stimulates SUMO modification of RanGAP but not p53 in vitro. RanBP2 does not have a RING domain and shows no homology to the PIAS family of SUMO E3 ligases.
17. Liu B., Liao J., Rao X., Kushner S.A., Chung C.D., Chang D.D., Shuai K. Inhibition of Stat1-mediated gene activation by PIAS1. Proc. Natl. Acad. Sci. U.S.A. 95:1998;10626-10631.
18. Chung C.D., Liao J., Liu B., Rao X., Jay P., Berta P., Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 278:1997;1803-1805.
19. Kotaja N., Aittomaki S., Silvennoinen O., Palvimo J.J., Janne O.A. ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. Mol. Endocrinol. 14:2000;1986-2000.
20. Gross M., Liu B., Tan J., French F.S., Carey M., Shuai K. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene. 20:2001;3880-3887.
21. Megidish T., Xu J.H., Xu C.W. Activation of p53 by protein inhibitor of activated Stat1 (PIAS1). J. Biol. Chem. 277:2002;8255-8259.
22. Gong L., Millas S., Maul G.G., Yeh E.T. Differential regulation of sentrinized proteins by a novel sentrin- specific protease. J. Biol. Chem. 275:2000;3355-3359.
23. Nishida T., Tanaka H., Yasuda H. A novel mammalian Smt3-specific isopeptidase 1 (SMT3IP1) localized in the nucleolus at interphase. Eur. J. Biochem. 267:2000;6423-6427.
24. Nishida T., Kaneko F., Kitagawa M., Yasuda H. Characterization of a novel mammalian SUMO-1/Smt3-specific isopeptidase, a homologue of rat axam, which is an axin-binding protein promoting beta-catenin degradation. J. Biol. Chem. 276:2001;39060-39066.
25. Hang J., Dasso M. Association of the human SUMO-1 protease SENP2 with the nuclear pore. J. Biol. Chem. 277:2002;19961-19966.
26. Best J.L., Ganiatsas S., Agarwal S., Changou A., Salomoni P., Shirihai O., Meluh P.B., Pandolfi P.P., Zon L.I. SUMO-1 Protease-1 (SuPr-1) regulates gene transcription through PML. Mol. Cell. 10:2002;843-855. • The authors identify the SUMO protease SuPr-1 as an activator of c-jun dependent transcription. SuPr-1 localizes to PML nuclear bodies and removes SUMO-1 from PML but not RanGAP1 in vivo. Binding of wild-type or a catalytically inactive mutant of SuPr-1 to SUMO-modified PML alters localization of several proteins found in PML nuclear bodies including PML and CBP. This study shows that SUMO proteases may regulate transcription factor activity by multiple mechanisms.
27. Bies J., Markus J., Wolff L. Covalent attachment of SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. J. Biol. Chem. 277:2002;8999-9009.
28. Kim J., Cantwell C.A., Johnson P.F., Pfarr C.M., Williams S.C. Transcriptional activity of CCAAT/enhancer-binding proteins is controlled by a conserved inhibitory domain that is a target for sumoylation. J. Biol. Chem. 277:2002;38037-38044. • In this study, the authors show that a previously identified inhibitory domain in C/EBP is a site of SUMO-modification. This domain inhibits transcriptional activation in a copy-number-dependent manner, both in cis and in trans, dependent on the integrity of the consensus SUMO acceptor site.
29. Dennig J., Beato M., Suske G. An inhibitor domain in Sp3 regulates its glutamine-rich activation domains. EMBO J. 15:1996;5659-5667.
30. Iniguez-Lluhi J.A., Pearce D. A common motif within the negative regulatory regions of multiple factors inhibits their transcriptional synergy. Mol. Cell Biol. 20:2000;6040-6050.
31. Hong Y., Rogers R., Matunis M.J., Mayhew C.N., Goodson M.L., Park-Sarge O.K., Sarge K.D., Goodson M. Regulation of heat shock transcription factor 1 by stress-induced SUMO- 1 modification. J. Biol. Chem. 276:2001;40263-40267. • In this paper, the authors show that heat shock transcription factor 1, HSF1, is post-translationally modified by SUMO-1 upon exposure to elevated temperatures. SUMO-1 modification is shown to stimulate DNA binding by HSF1 in vitro. Upon heat shock, wild-type HSF, but not a mutant in the SUMO acceptor lysine, is localized to nuclear bodies.
32. •], post-translational modification by SUMO-1 is here shown to increase DNA-binding activity of HSF2 in vitro.
33. Lachner M., Jenuwein T. The many faces of histone lysine methylation. Curr. Opin. Cell Biol. 14:2002;286-298.
34. Desterro J.M., Rodriguez M.S., Hay R.T. SUMO-1 modification of IκBα inhibits NF-κB activation. Mol. Cell. 2:1998;233-239.
35. Braun H., Koop R., Ertmer A., Nacht S., Suske G. Transcription factor Sp3 is regulated by acetylation. Nucleic Acids Res. 29:2001;4994-5000.
36. Mahajan R., Gerace L., Melchior F. Molecular characterization of the SUMO-1 modification of RanGAP1 and its role in nuclear envelope association. J. Cell Biol. 140:1998;259-270.
37. Matunis M.J., Wu J., Blobel G. SUMO-1 modification and its role in targeting the Ran GTPase-activating protein, RanGAP1, to the nuclear pore complex. J. Cell Biol. 140:1998;499-509.
38. Chakrabarti S.R., Sood R., Nandi S., Nucifora G. Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell- cycle-dependent assembly into nuclear bodies. Proc. Natl. Acad. Sci. U.S.A. 97:2000;13281-13285.
39. Zhong S., Muller S., Ronchetti S., Freemont P.S., Dejean A., Pandolfi P.P. Role of SUMO-1-modified PML in nuclear body formation. Blood. 95:2000;2748-2752.
40. Ishov A.M., Sotnikov A.G., Negorev D., Vladimirova O.V., Neff N., Kamitani T., Yeh E.T., Strauss J.F. III, Maul G.G. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147:1999;221-234.
41. Jang M.S., Ryu S.W., Kim E. Modification of Daxx by small ubiquitin-related modifier-1. Biochem. Biophys. Res. Commun. 295:2002;495-500.
42. Sternsdorf T., Jensen K., Reich B., Will H. The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J. Biol. Chem. 274:1999;12555-12566.
43. Seeler J.S., Dejean A. SUMO: of branched proteins and nuclear bodies. Oncogene. 20:2001;7243-7249.
44. Zhong S., Salomoni P., Pandolfi P.P. The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2:2000;E85-E90.
45. Carey M. The enhanceosome and transcriptional synergy. Cell. 92:1998;5-8.
46. Poukka H., Karvonen U., Janne O.A., Palvimo J.J. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. U.S.A. 97:2000;14145-14150.
47. Conaway R.C., Brower C.S., Conaway J.W. Emerging roles of ubiquitin in transcription regulation. Science. 296:2002;1254-1258.
48. Kuras L., Rouillon A., Lee T., Barbey R., Tyers M., Thomas D. Dual regulation of the met4 transcription factor by ubiquitin-dependent degradation and inhibition of promoter recruitment. Mol. Cell. 10:2002;69-80. • Met4 activates expression of the MET genes in yeast when methionine is limiting. In minimal media supplemented with methionine, ubiquitination of Met4 leads to proteasome-dependent degradation. In this paper, the authors show that in rich media Met4 is modified by ubiquitin but remains stable. Under these conditions, ubiquitinated Met4 is not recruited to the MET promoters but is recruited to the SAM genes. The results suggest a role for post-translational modification by ubiquitin in promoter-specific regulation of transcription.